Bart Clarke

Get full text access Log in, subscribe or purchase for full access. References 1. Khan, AA ∙ Bilezikian, JP ∙ Brandi, ML ∙ et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop J Bone Miner Res. 2022; 37:2568-2585 2. Khan, AA ∙ Guyatt, G ∙ Ali, DS ∙ et al. Management of hypoparathyroidism J Bone Miner Res. 2022; 37:2663-2677 3. Khan, AA ∙ Ali, DS ∙ Bilezikian, JP ∙ et al.

You've successfully added Bone/Mineral Metabolism to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: At 52 weeks, 81% of adults receiving palopegteriparatide had normalized serum calcium levels without needing conventional therapy. Mean bone mineral density scores remained normal at 1 year.

Author notes These authors contributed equally: Michael T. Collins, Gemma Marcucci Authors and Affiliations Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA Michael T.